Fastest growing modality in 1H25: Of WuXi's 864 integrated projects in 1H25, 168 projects (or 19%) were bi-/multi-specific antibodies. Revenue from these contracts was up >200% YoY in 1H25, followed by ADCs (up 50% YoY). In addition to CD20/ CD3, WuXi's proprietary CD3 T-cell engager platform also engineered bi-/multi- specifics, such as CD3xCD19, CD3xPSMA, and CD3xCD19xCD20. TQB2825 has been tested in combination with immunochemotherapy and chemotherapy alone in two Phase 2 trials: TQB2825+R-CHOP (trial li ...

每经AI快讯，9月17日，药明生物公众号宣布，其位于无锡的生物药原液一厂（MFG1）、生物药原液 二厂（MFG2）和生物药制剂五厂（DP5）获得土耳其药品和医疗器械管理局的GMP认证。 ...

人民财讯9月17日电，9月17日，药明生物宣布，其位于无锡的生物药原液一厂(MFG1)、生物药原液二 厂(MFG2)和生物药制剂五厂(DP5)获得土耳其药品和医疗器械管理局(TITCK)的GMP认证。这是药明生 物首次通过土耳其TITCK的GMP审计。 ...

Group 1 - The innovative drug sector has become a focal point in the secondary market this year, raising questions about whether this enthusiasm is translating to the primary market and if there is a shift in capital investment attitudes towards innovative drugs [1] - WuXi Biologics held its first "M Powering Global Success" CRDMO+ Open Day, where executives discussed trends in biopharmaceutical innovation, international expansion, and quality system development [1] - The CEO of WuXi Biologics noted that while the Chinese biopharmaceutical investment market has not fully recovered, there are signs of improvement in cutting-edge fields such as ADC and bispecific antibodies [1] Group 2 - More companies are willing to invest in First-in-Class projects, indicating a shift from fast follow strategies to genuine source innovation [2] - WuXi Biologics is focusing on high-potential areas such as monoclonal antibodies, bispecific/multispecific antibodies, and ADCs, with expectations that 10 products in the monoclonal antibody sector could exceed $5 billion in sales, and 5 of those could surpass $10 billion [2] - The company demonstrates significant production efficiency, completing technology transfer to PPQ in just 6 months, which is 3-6 months faster than the industry average, and can reduce this to 3.5 months with an accelerated process [2]

September 9, 2025 07:53 PM GMT WuXi Biologics Cayman Inc | Asia Pacific Global Healthcare Conference Takeaways As part of preparation for our GHC, WuXi's updated presentation deck provides granularity on the major areas of innovation in the biologics space. Key Takeaways Top modalities driving project starts year-to-date: Of WuXi's 864 integrated projects as of mid-2025, a majority were still mAbs (38%). But the highest-growth modalities were bi-/multi-specifics (+37% YoY) and ADCs (+35% YoY). These two mod ...

SHANGHAI, Sept. 9, 2025 /PRNewswire/ --Â WuXi Biologics (2269.HK), a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), recently launched the "WuXi Biologics Green CRDMO White Paper" at its first CRDMO Open Day event, sharing the end-to-end Green CRDMO solution for biologics and driving the sustainable development of the global biologics industry supply chain. Last November, the company's Green CRDMO solution was also featured in the "20 Case Examples for 20 Years" report ...

智通财经APP讯，药明生物(02269)发布公告，于2025年9月8日，因期权获行使而发行合计605.75万股。 ...

药明生物(02269)发布公告，于2025年9月8日，因期权获行使而发行合计605.75万股。 ...

FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 第 1 頁 共 6 頁 v 1.3.0 FF305 | 就根據股份計劃授予發行人的董事的股份獎勵或期權而發行新股或轉 | 2). | | 6,000,000 | 0.14703 % | HKD | 1.29 | | | --- | --- | --- | --- | --- | --- | --- | --- | | | 讓庫存股份 - 涉及新股 | | | | | | | | 根據公司於2016年1月5日採納之首次公開發售前購股權計劃 (於 | | | | | | | | | | 2016年8月10日修訂)為行使期權而發行普通股 | | | | | | | | | 變動日期 | 2025年9月8日 | | | | | | | | 於下列日期結束時的結存 (註5及6) | 2025年9月8日 | 4,086,953,756 | | 0 | | 4,086,953,756 | | B. 贖回/購回股份 (擬註銷但截至期終結存日期尚未註銷) (註5及6) | | | | | | | | | | 1). 購回 ...

2011年，陈智胜博士从美国回到中国。与很多海归科学家选择创业不一样，陈智胜加入了药明康德 （603259）（SH603259，股价110.60元，市值3264.00亿元），彼时，无锡马山到处都是隆隆作响的打 桩声。2014年，药明生物（HK02269，股价38.98港元，市值1591.00亿港元）从药明康德分拆出来，陈 智胜担任药明生物CEO（首席执行官）。 "（十年前）我还记得有天晚上和几个同行在苏州BioBAY聊天，大家还在畅想，五年后，中国可以有第 一个自己的创新药、二十年后有5到10个创新药就不错了，那就非常好了。"在9月4日的药明生物首届 CRDMO+ 开放日活动上，陈智胜笑言，台下很多嘉宾是中国创新药最早的参与者，更是行业发展的推 动者。如今看来，十年前大家还是太保守了，这些年中国生物创新药"做得比说得多"，真正实现了弯道 超车。 十年时间，中国创新药已经跃升为全球第一梯队。2025年前5个月，中国生物创新药授权交易金额达到 216亿美元，全球大型制药交易中来自中国创新药的占比达到38%。 在今年1月召开的JPM大会（第43届摩根大通医疗健康大会）上，陈智胜见了120个客户。创新药BD （商务拓 ...